Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer

Recent advances in molecular profiling technologies allow genetic driver events in individual tumors to be identified. The hypothesis behind this ongoing molecular profiling effort is that improvement in patients’ clinical outcomes will be achieved by inhibiting these discovered genetic driver event...

Descripción completa

Detalles Bibliográficos
Autores principales: Aung, Kyaw L., Stockley, Tracy L., Serra, Stefano, Kamel-Reid, Suzanne, Bedard, Philippe L., Siu, Lillian L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2016
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002925/
https://www.ncbi.nlm.nih.gov/pubmed/27626067
http://dx.doi.org/10.1101/mcs.a001016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002925/
https://www.ncbi.nlm.nih.gov/pubmed/27626067
http://dx.doi.org/10.1101/mcs.a001016

Ejemplares similares